Sandhill Capital Partners’s Gain Therapeutics GANX Stock Holding History

Sandhill Capital Partners’s Portfolio GANX Stock Details GANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$29.9K	Hold	15,400	–	–	﹤0.01%	95
2025 Q4	$49.6K	Hold	15,400	–	–	﹤0.01%	104
2025 Q3	$27.3K	Hold	15,400	–	–	﹤0.01%	105
2025 Q2	$27.7K	Hold	15,400	–	–	﹤0.01%	97
2025 Q1	$29.4K	Hold	15,400	–	–	﹤0.01%	88
2024 Q4	$33.3K	Hold	15,400	–	–	﹤0.01%	92
2024 Q3	$27.4K	Buy	+15,400	New	+$19.4K	﹤0.01%	90

Other funds holding GANX

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

PCM

Potomac Capital Management New York $115M AUM

Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

DCM

DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Sandhill Capital Partners's GANX Position: Q1 2026 in Review

Sandhill Capital Partners held its Gain Therapeutics (GANX) position steady in Q1 2026 at 15,400 shares worth $29.9K. The position accounts for ﹤0.01% of the portfolio, ranked #95.

Sandhill Capital Partners first reported a position in GANX in Q3 2024 and has held it in 7 quarters since. The position peaked at $49.6K in Q4 2025. 42 funds tracked by Wall St. Rank hold GANX as of Q1 2026.

Sandhill Capital Partners held 15,400 shares of Gain Therapeutics worth $29.9K as of Q1 2026.
Sandhill Capital Partners left its Gain Therapeutics share count unchanged in Q1 2026.
Gain Therapeutics made up ﹤0.01% of Sandhill Capital Partners's portfolio in Q1 2026, its #95 holding.
Sandhill Capital Partners first reported a position in Gain Therapeutics in Q3 2024 and has held it in 7 quarters since.
Sandhill Capital Partners's Gain Therapeutics position peaked at $49.6K in Q4 2025.
42 funds tracked by Wall St. Rank held Gain Therapeutics as of Q1 2026.

Based on Sandhill Capital Partners's 13F filing for Q1 2026, filed 14 May 2026.